Target intelligence / Profile preview

Immunoglobulin G Fc region N-linked glycan at Asparagine 297 (IgG Fc Asn297 glycan)

Target
IgG Fc Asn297 glycan
Molecular classification
Post-translational modification, Glycan, Immune signaling component
01

Overview

The N-linked glycan at Asparagine 297 (Asn297) is a critical structural component located within the CH2 domain of the Fc region of Immunoglobulin G (IgG) (Jefferis, 2009). This biantennary complex-type oligosaccharide is essential for maintaining the open conformation of the Fc region, which is required for binding to Fc gamma receptors (FcγRs) and the C1q complement protein (Pereira et al., 2018). Variations in the glycan's composition—specifically the presence of fucose, galactose, sialic acid, and bisecting N-acetylglucosamine—act as a molecular switch to modulate the antibody's pro- or anti-inflammatory activities (Wang & Amin, 2014). In oncology, therapeutic antibodies are often glycoengineered to lack core fucose (afucosylation) at Asn297, which significantly enhances their affinity for FcγRIIIa and boosts antibody-dependent cellular cytotoxicity (ADCC) against tumor cells (Pereira et al., 2018). Conversely, in autoimmune diseases, the enzymatic removal of this glycan by bacterial enzymes like Endoglycosidase S (EndoS) is being explored as a strategy to neutralize pathogenic autoantibodies by preventing them from activating effector cells (Sjögren et al., 2015). Consequently, the Asn297 glycan is a central target for optimizing the efficacy and safety of monoclonal antibody therapies.

Other names
Asn297 glycanFc-linked oligosaccharideIgG glycosylation siteN297 glycanFc N-glycan
02

Mechanism of action

Modulation of Fc gamma receptor (FcγR) affinity through glycoengineering (e.g., afucosylation) or enzymatic cleavage to alter immune effector functions (Jefferis, 2009; Pereira et al., 2018).

03

Biological functions

Immune responseAntibody-dependent cellular cytotoxicity (ADCC)Complement-dependent cytotoxicity (CDC)Fc receptor bindingProtein structural stability
04

Disease associations

CancerAutoimmune diseaseInflammation
05

Safety considerations

Infusion-related reactionsEnhanced cytokine release syndromePotential immunogenicity of modified glycans
06

Interacting drugs

Obinutuzumab

5 more in the full profile.

07

Biomarkers

IgG glycan profile (e.g., fucosylation levels)FcγRIIIa (CD16a) V158/F158 polymorphism status

Beyond the preview

Go deeper on Immunoglobulin G Fc region N-linked glycan at Asparagine 297 (IgG Fc Asn297 glycan).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin G Fc region N-linked glycan at Asparagine 297 (IgG Fc Asn297 glycan).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call